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Inflammation is central to pathogenic processes in diabetes mellitus and the metabolic
syndrome and particularly implicates innate immunity in the development of
complications. Inflammation is a primary event in Type 1 diabetes where infectious
(viral) and/or autoimmune processes initiate disease; in contrast, chronic inflammation is
typical in Type 2 diabetes and is considered a sequel to increasing insulin resistance and
disturbed glucose metabolism. Diabetic retinopathy (DR) is perceived as a vascular and
neurodegenerative disease which occurs after some years of poorly controlled diabetes.
However, many of the clinical features of DR are late events and reflect the nature of the
retinal architecture and its cellular composition. Retinal microvascular disease is, in fact, an
early event pathogenetically, induced by low grade, persistent leukocyte activation which
causes repeated episodes of capillary occlusion and, progressive, attritional retinal
ischemia. The later, overt clinical signs of DR are a consequence of the retinal ischemia.
Metabolic dysregulation involving both lipid and glucose metabolism may lead to
leukocyte activation. On a molecular level, we have shown that macrophage-restricted
protein tyrosine phosphatase 1B (PTP1B) is a key regulator of inflammation in the
metabolic syndrome involving insulin resistance and it is possible that PTP1B
dysregulation may underlie retinal microvascular disease. We have also shown that
adherent CCR5+CD11b+ monocyte macrophages appear to be selectively involved in
retinal microvascular occlusion. In this review, we discuss the relationship between early
leukocyte activation and the later features of DR, common pathogenetic processes
between diabetic microvascular disease and other vascular retinopathies, the
mechanisms whereby leukocyte activation is induced in hyperglycemia and dyslipidemia,
the signaling mechanisms involved in diabetic microvascular disease, and possible
interventions which may prevent these retinopathies. We also address a possible role for
adaptive immunity in DR. Although significant improvements in treatment of DR have been
made with intravitreal anti-VEGF therapy, a sizeable proportion of patients, particularly with
sight-threatening macular edema, fail to respond. Alternative therapies targeting
inflammatory processes may offer an advantage.
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The advancing epidemic of diabetes mellitus, intertwined with a
coincident epidemic of obesity, is one of the major public health
crises facing developed and developing nations alike (1, 2). Of the
two main major forms of diabetes, Type 2 far outweighs Type 1
diabetes (T1D) in prevalence and presents modern health care
systems with the greater challenge (3–5). T1D is considered an
autoimmune disease (6–8), possibly induced by a viral infection (9,
10) with an acute onset involving insulitis and islet cell infiltration
but persisting as a chronic disease (11, 12), while Type 2 diabetes
(T2D) is a chronic disease, brought on by metabolic dysregulation
and insulin resistance (13, 14). Although etiologically different, both
conditions are characterized by hyperglycemia and dyslipidemia
which are considered major risk factors for development of the
shared macrovascular and microvascular complications as well as
neurological dysfunction (15); moreover, the two conditions can co-
exist (4). The pathobiology of both T1D and T2D and their
macrovascular complications is grounded in inflammation but
there is greater debate concerning microvascular disease (16, 17).
For instance, diabetic peripheral neuropathy, nephropathy, and
retinopathy are microvascular complications in which small vessel
endothelial cells seem to be the focus of the attack (18, 19). In
contrast, macrovascular atheromatous disease is considered to be
primarily a dyslipidemic/inflammatory process (20). This review
examines the relationship between dysregulated metabolism and
inflammation in the development of diabetic retinopathy.WHAT TRIGGERS THE DEVELOPMENT OF
COMPLICATIONS IN DIABETES?
The pathogenesis of the complications of diabetes is frequently
considered in terms of the cellular metabolic and signaling
pathways which lead to organ dysfunction. However, signaling
pathways vary between tissues and cells and so their disruption is
equally tissue or cell specific. Even the vessels, particularly
microvessels, are tissue specific and respond differently at each site.
Bone marrow cells are also subject to the effects of the altered
metabolic state of diabetes but by being distributed to all tissues, their
altered functional state becomes a common tissue denominator.
Thus, it has become clear that metabolically altered bone marrow
derived cells contribute to organ dysfunction in diabetes (21–24).
The question is do bone marrow derived cells initiate organ
dysfunction and if so, do they have a direct effect on organ
function or do they do so through causing vasculopathy? It is
therefore important to consider altered metabolism in a cell-
specific context. It follows that a second important consideration is
deciding when, in the course of developing diabetes, does the altered
metabolic state affect each cell type and tissue equally: specifically,
once beta cell loss or dysfunction is established and hyperglycemia
cannot be controlled, how well can tissues adapt to the new
conditions before becoming dysfunctional or permanently damaged?
The difficulty in interpreting the pathological change lies in the
lack of information concerning the initial events in diabetes and in
its complications. For this reason, the United States National
Institutes of Health (NIH) has initiated a prospective HumanFrontiers in Immunology | www.frontiersin.org 2Pancreatic Analysis Programme to track the relationship between
immune cell abnormality and beta cell damage (8). Meantime,
some of the most informative data derive from recent
collaborative studies revealing correlations between proinsulin
expression and assigned insulitis lymphocyte composition in
endotypes of T1D (25). Hyperglycemia is a marker for the onset
of diabetes but even the threshold for this is quite wide. Normal
blood glucose measurements are considered to be below 5.5 mM/L
(fasting), while levels between 5.5 and 7.0 mM/L are described as
pre-diabetes and a fasting blood glucose >7.0 mM/L on more than
one occasion sets the diagnostic criteria for diabetes mellitus (26,
27). If endothelial dysfunction is a direct result of the systemic
metabolic changes and exposure to toxic levels of glucose, do these
blood levels of glucose predict changes in endothelial cell health?
In culture, DNA synthesis declines markedly in retinal endothelial
cells in medium containing >2.0 mM glucose (28) and is
dependent on glucose uptake via GLUT 1 and 3. This threshold
of 2.0 mM glucose is much lower than acceptable blood glucose
levels, suggesting that there are other factors which maintain
endothelial cell health in normoglycemia in vivo, i.e., up to
5.5mM/L. Indeed, there are damage limitation factors in the
circulation which protect the endothelium, such as acute phase
reactants (29–31) and circulating antiproteases (32, 33), while the
number and activation status of the circulating cells in the
hyperglycemic milieu must also have an effect (24, 34).WHEN DO THE COMPLICATIONS OF
DIABETES BECOME IRREVERSIBLE?
In consideration of the onset of diabetes and when complications are
likely to develop, it is probably more appropriate to envisage a
progressively developing situation which is potentially reversible or
repairable (35), but is one in which, gradually, insulin/leptin/
glucagon-based control of central glucose and lipid homeostasis
fails (36). Indeed, clinical microvascular disease in diabetes is not
inevitable (37). Tissues and vessels exposed to pendulum swings of
increasing metabolic stress can often adapt and survive, but in many
cases, a point is reached where overt irreversible damage occurs (38).
In the case of T1D, acute onset damage with loss of islet cell function
takes place against a background of infectious/autoimmune
inflammation in which an active immune response proceeds from
the outset, and so an approximate time-of-onset can be determined.
In T2D where obesity and progressive adipose tissue macrophage
(ATM) activation provide the backdrop to increasing insulin
resistance and low-level chronic inflammation, it is much more
difficult to pinpoint either the onset of diabetes or when tissue
damage occurs. In the case of diabetic retinopathy (DR), clinical
signs manifest some time (often years) after the onset of diabetes;
however, in T2D DR paradoxically may be the presenting sign, with
the implication that an underlying diabetic state has been present but
clinically “silent” for years. In fact, it is estimated that for every
known case of T2D there is another undiagnosed (39, 40). The
prolonged time for development of complications has been
incorporated into a notion of “metabolic memory” but recent
analysis has poured cold water on this idea and ascribes the risk of
complications to a cumulative exposure to high glucose levels (41).November 2020 | Volume 11 | Article 583687
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initial pathological events of microvascular disease in diabetes. If
it is not possible to determine when the disease begins, it is even
more difficult to decide what constitutes first evidence of the
complications and, in a sense, this is dependent on what signs are
sought and the methods used to detect them. This applies
especially so to DR in which most of the classically recognized
clinical and pathological signs are late and even secondary
events. For this reason, experimental models, in which the
onset of hyperglycemia and dysregulated lipid metabolism can
be more definitively timed, at least allow determination of the
earliest cellular changes and deviations from homeostasis. In
addition, if it is accepted that dysregulated metabolism is the
cause of the microvascular complications of diabetes, it follows
that the onset of the damaging insult coincides with the onset of
the metabolic change, i.e., the onset of diabetes.IS INFLAMMATION IN DIABETES A
DIRECT OR AN INDIRECT CAUSE OF
COMPLICATIONS?
The next question is whether metabolic dysregulation in diabetes
is the direct cause of the complications (e.g., via toxic metabolites)
or whether they arise from secondary effects on another systemFrontiers in Immunology | www.frontiersin.org 3(e.g., immune/inflammatory homeostasis). The liver and adipose
tissue are the engines of metabolism responsive to signals from
many sources. Control of blood glucose, lipid metabolism, and
body weight through insulin and leptin signaling are both
peripherally and centrally regulated (42). Signaling via the
insulin receptor/IRS pathway and the leptin/leptin receptor
(LepRb) involves downstream JAK-2/STAT3/5, PI3 Kinase/Akt,
and the MAP kinase pathways in hepatocytes and adipocytes with
phosphorylation of the insulin receptor (InsR) and the leptin
receptor (LepRb) at several sites on the cytoplasmic tails of the
molecules (Figure 1). Recent studies have highlighted the role of
microRNA’s which control the relevant signaling networks in
adipose tissue, but only a few are altered in obese individuals (43).
This offers an opportunity to select these specific microRNA’s as
targets for therapy and/or as biomarkers.
Regulated metabolism not only dictates the health of
parenchymal tissues but underpins immune cell homeostasis
(44, 45). Granulocytes have few mitochondria and do not
consume oxygen to any great extent; instead, they generate
ATP for energy by aerobic glycolysis (lactate production) even
in states of normoxia (the Warburg effect) (46). Macrophages,
dendritic cells and T cells in quiescence generate ATP for energy
requirements by oxidative phosphorylation (OXPHOS) but
switch to aerobic glycolysis when activated (47). In macrophages,
this switch in metabolism is reflected in proinflammatory (so-calledFIGURE 1 | Model of PTP regulation of central leptin and insulin signaling. When circulating leptin binds to its receptor LepRb, the associated tyrosine kinase JAK2
autophosphorylates and phosphorylates specific tyrosine residues along the intracellular tail of the LepRb. Phosphorylation of Y985 allows for recruitment of the PTP
SHP2 which mediates downstream ERK1/2 signaling, while phosphorylation of Y1138 allows for activation of STAT3 which regulates transcription of key
neuropeptides involved in energy homeostasis. Unlike leptin signaling, insulin binding to its receptor results in receptor autophosphorylation at tyrosine residues
1158, 1162, and 1163. This allows for recruitment of the effector IRS, which upon phosphorylation can recruit adaptor molecules and mediate downstream PI3K and
ERK1/2 signaling. In contrast to SHP2 which positively regulates leptin signaling, several PTPs can negatively regulate central leptin and insulin signaling. PTP1B
inhibits leptin and insulin signaling by dephosphorylating JAK2 and the IR, respectively. Additionally, PTP1B has been implicated in dephosphorylating the
downstream leptin/insulin signaling protein Tub. Like PTP1B, RPTPe has been shown to inhibit leptin signaling at the level of JAK2, while TCPTP negatively regulates
leptin signaling via dephosphorylation of STAT3. PTEN antagonizes neuronal insulin-induced PI3K signaling via dephosphorylation of the phospholipid PIP3 into PIP2,
resulting in decreased K+ ATP channel conductance [from Tsou and Bence (42)]. Figure created with Biorender.com.November 2020 | Volume 11 | Article 583687
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(Figure 2). In both T1D and T2D, dysregulated glucose and lipid
metabolism drive the chronic inflammatory state which manifests
with increased levels of inflammatory biomarkers and acute phase
reactants (29, 49, 50). Some such as C-reactive protein (CRP) and
triglyceride-rich lipoproteins exert a direct pro-inflammatory effect
by activating blood monocytes (20, 51).INSULIN RESISTANCE, INFLAMMATION,
AND DIABETES
(a) A Role for Adipose Tissue
Macrophages
Obesity-induced IR is a consequence of low-grade chronic
inflammation in adipose tissue (AT) (52, 53). AT contains an
extensive store of resident macrophages and dendritic cells
(ATM, ATDC) whose function is to maintain tissue
homeostasis. However, with increasing lipid deposition and
obesity, ATM increase in number and activation status, and
their cytokine secretion contributes to the low-level chronic
inflammatory status associated with the metabolic syndrome
(MS) and diabetes in particular (54). Activation of ATMs is
mediated via cGAS-cGAMP-STING which, signaling throughFrontiers in Immunology | www.frontiersin.org 4TANK binding kinase 1 (TBK1), leads to phosphorylation and
nuclear translocation of the transcription factor interferon
regulatory factor 3 (IRF3). This, together with nuclear factor-
kappa B (NF-kB) activation and nuclear translocation, leads to
production of several inflammatory cytokines including Type 1
Interferons (IFN) (55–57). TBK1 activation status in particular
seems to be an important determinant of homeostasis vs.
inflammation via ATM (58). However, the role of TBK1 may
be double-edged since it promotes phosphorylation and
inactivation of NFkB-inducing kinase (NIK) (58) (Figure 3).
In contrast to ATM, the role of ATDC in obesity-induced IR and
the MS is less clear. While they seem to be important in
regulating AT CD4 and CD8 T cell homeostasis, disabling
antigen presenting capacity in IgtxCreMHC Class II−/− mice
had little effect on overall inflammation levels (59, 60).
However, since all types of T cells, including T regulatory cells
(Tregs), would fail to be activated in these experiments, the
precise role of ATDC remains to be resolved.
(b) Insulin Resistance Develops in
Proportion to Adipose Tissue
Macrophages
How does IR develop in AT? As adipocytes hypertrophy and
accumulate increasing amounts of lipid, they become activatedFIGURE 2 | Metabolic reprogramming in macrophage polarization. LPS and IFN-g induce M1 macrophages. Metabolism in M1 macrophages is characterized by
increased glycolysis and PPP activity, and a broken TCA cycle that leads to metabolite accumulation. M2 macrophages display a more oxidative metabolic profile,
with a high reliance on the TCA cycle, utilizing OXPHOS and exhibiting high levels of FAO. Inhibition of glycolysis by 2-DG leads to an oxidative M2 phenotype [from
Corcoran and O’Neill (48)]. Figure created with Biorender.com. * PKM2: pyruvate kinase M2.November 2020 | Volume 11 | Article 583687
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AT, particularly visceral AT, becomes the seat of inflammation.
Pro-inflammatory bone marrow derived myeloid cells, as well as
T cells (cytotoxic CD8+, Th1 and Th17 proinflammatory cells)
and NK cells, are recruited to AT while there is a concomitant
reduction in the normal complement of Tregs [reviewed in (61)].
A particular subset of AT fibroblasts, the interleukin (IL)-33+
putative mesenchymal stem cell (mSC), increases inversely in
proportion to the reduction in AT Tregs contributing to the
overall increase in AT inflammation in diabetes. Potentially
Tregs have the ability to reverse the deleterious effects of
obesity (62) and in normal mice, over time, they become the
predominant T cells in AT. Thus, an apparent protective effect of
AT Tregs is lost in diabetic mice (63). At the same time, pro-
inflammatory macrophages alternate with arginase+ alternatively
activated but pro-fibrotic macrophages which, through induction
by AT derived mSCs, further alter the stromal architecture of AT
(64). TNFa secretion by ATMs particularly influences the
development of the MS as shown by the failure of TNFa−/−
mice to develop diabetes and insulin resistance (IR) (65).
However, arginase+ alternatively activated ATMs may also
have a protective role through secretion of IL-10 (66–68).
Precisely how adipocytes modify ATM behavior and function
is unclear but recent studies suggest microRNA’s and long non-
coding RNA’s (lncRNAs) may play a role. lncRNA’s have been
shown to have extensive regulatory functions, mostly involving
translation and transcription of proteins such as metastasis
associated lung adenocarcinoma transcript 1 (Malati), Nuclear
Enriched Abundant Transcript 1 (Neat) and lncDC which
regulates dendritic cell differentiation via mir155 (69); forFrontiers in Immunology | www.frontiersin.org 5instance, lncDC binds to STAT3 to prevent its de-
phosphorylation by SHP-1 [reviewed in (70)]. These short and
long RNA moieties can be secreted from adipocytes as exosomes
into the extracellular micorenvironment where they exert
local control of cell behavior [reviewed in (71)]. This affects all
tissues and can modify disease processes. For instance, during
aging, certain lncRNAs are generated in white AT which
are linked to inflammatory pathways implicating AT and
obesity with age-related degenerative changes (72). In another
example, pyroptosis, a process involving activation of the
inflammasome, is controlled by the lncRNA NEAT1 in
diabetic nephropathy through the action of the mir34c/NLRP3
axis (73). Most recently, a novel lncRNA, macrophage
inflammation-suppressing transcript (74) has been described
which is lost in obese mice and is reduced in ATM from obese
patients (75). In sum, visceral AT and its complement of
inflammatory cells, especially ATMs, is a highly dynamic
cellular structure under a wide variety of intrinsic and extrinsic
epigenetic controls. These become dysregulated in obesity and
AT becomes a driver of systemic inflammation which is the
phenotypic signature of the MS (76) and is a central feature of
diabetes (77).
Importantly, these AT changes and the development of the
MS often precede overt diabetes. Experimentally the MS can be
modelled by dietary manipulation, as in the high-fat diet (HFD)
mouse model (78). Such mice have increased serum adipokines,
elevated triglycerides and altered levels of HDL and LDL
cholesterol in blood, IR, and transient hyperglycemia, and go
on to develop signs of atherosclerosis (79). In addition, they have
a pro-inflammatory systemic signature. Metabolic activity inFIGURE 3 | Tank-binding protein kinase 1 (TBK1) operates at the intersection of energy expenditure and inflammation. For instance, TBK1 deficiency attenuates
HFD-induced obesity but exaggerates inflammation through its effects on NF-kB–inducing kinase (NIK). TBK1 represses energy expenditure by phosphorylating and
inhibiting AMPK and to the serine-threonine kinase Unc-51-Like Autophagy Activating Kinase 1 (ULK1). The combined effects of TBK1 are to attenuate NF-kB
activation and mediate the anti-inflammatory effect of AMPK [from Zhao et al. (58)].November 2020 | Volume 11 | Article 583687
Forrester et al. Inflammation, Phosphatases, and Diabetic Retinopathymacrophages and DC is regulated through activity of kinases and
phosphatases but differentially from parenchymal (e.g., liver)
cells. Each cell type in fact plays a specific role. For instance,
TBK1 by phosphorylating mTORC-1 exerts a negative feedback
effect on STING (80) and thus exerts a dual role on macrophage-
induced inflammation (Figure 4). In contrast, we have shown
that deletion of macrophage specific protein tyrosine
phosphatase-1B (PTP1B) in LysM-PTP1B mice markedly
reduces HFD-associated inflammation and also protects mice
against LPS-induced endotoxemia (81). These effects were
associated with increased levels of phosphorylated (p)-STAT3
and increased production of IL-10. Thus, regulation of
metabolism (body weight) and the associated inflammation
(endotoxemia, leukocyte activation) appear to be under control
of resident ATMs rather than adipocytes and hepatocytes per se.
(c) Are Insulin Resistance and Chronic
Inflammation the Host’s Defense Against
Overnutrition?
What is the stimulus for bone marrow derived macrophages
(BMDMs) and ATMs to shift to a pro-inflammatory mode? As
Donath et al. put it “…… three key features of T2D—namely,
insulin resistance, decreased insulin secretion and glycosuria—
are primarily mechanisms that protect against overnutrition by
preventing the accumulation and overloading of tissues with cell
nutrients” (82). IL-1 stimulation of insulin secretion by
pancreatic beta cells via diacyl glycerol protein kinase C
signaling underpins this concept (83). Islet beta cells have high
levels of IL-1r and in response to increased glucose undergoFrontiers in Immunology | www.frontiersin.org 6inflammasome activation and secrete IL-1, thereby attracting
further islet infiltration by macrophages which sets a positive
feedback loop for IL-1 secretion [see ref. (82)]. Increased glucose
metabolism and hexokinase activity alone in macrophages are
sufficient to act as pathogen/damage associated molecular
patterns (PAMP/DAMP) with production of pro-inflammatory
cytokines, particularly IL-1 (84) and this can even be induced
transiently by postprandial hyperglycemia (85). This sets the
wheels rolling for progressive beta cell apoptosis, insulin loss/
resistance, and persistent low level chronic local and systemic
inflammation which begin when ambient glucose levels are
above a threshold that cells can manage. However, loss of
pancreatic insulin in T1D and IR in T2D with their
consequent effects on glucose and lipid metabolism eventually
leads to ATM activation and increase in numbers. This is caused
by adipocyte increase in size, nutrient overload and apoptosis
which, as indicated above, further attracts monocyte/
macrophage infiltration (86).
ATM precursors/monocytes respond to pro-inflammatory
signals and arrive at their target tissue in an activated state
(23). Thus, circulating monocytes in obese and/or diabetic
individuals and in HFD fed/diabetic experimental animals
express markers of activation such as increased levels of
L-selectin, ROS and iNOS (87–91). Monocyte/myeloid cell
activation occurs in the early stages of diabetes and HFD-
induced obesity, and inflammatory biomarkers are elevated
before the onset of overt diabetes (92, 93). Although there may
be some local replication of F4/80+ yolk sac-derived resident
tissue macrophages (94), inflammatory macrophages such asFIGURE 4 | Activation of the cGAS-cGAMP-STING pathway mediates obesity-induced inflammation and metabolic disorders. Obesity reduces the expression levels of
disulfide bond A oxidoreductase like protein (DsbA-L) in adipose tissue, leading to mitochondrial stress and subsequent mtDNA release into the cytosol. Aberrant localization of
mtDNA in the cytosol activates the cGAS-cGAMPSTING pathway, leading to enhanced inflammatory gene expression and insulin resistance. Phosphorylated and activated
TBK1 exerts a feedback inhibitory role by promoting STING ubiquitination and degradation or stimulating phosphorylation-dependent degradation of NF-kB–inducing kinase
(NIK), thus attenuating cGAS-cGAMP STING–mediated inflammatory response [from Bai and Liu (80)]. Figure created with Biorender.com.November 2020 | Volume 11 | Article 583687
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which sustain vascular health (see below) (95), are mostly bone
marrow-derived (24, 96).
This process, i.e., recurrent cycles of immune cell activation
and inflammation, not only begins at the onset of the MS and
obesity/HFD disease, but actually represents the onset of these
disorders when the threshold of homeostasis is breached. The
logical conclusion is that this pro-inflammatory backdrop may
be the driver for the overt diabetic state and its complications
(82). The recent studies showing the benefit of anti–IL-1
antibodies in preventing macrovascular complications of
diabetes support this re-think (97, 98). As the disease
progresses, other factors contribute to and exacerbate the
underlying pro-inflammatory condition. These include AT
hypoxia, induced by the expansion of tissue outstripping its
capillary vascularization which may in fact be a result of capillary
occlusion and loss, due to intravascular leukocyte entrapment
and coagulation. The resultant tissue hypoxia promotes further
macrophage infiltration. In addition, alterations to the gut
microbiota which is a common feature in diabetic patients are
associated with increased gut barrier leakiness and the entry of
pro-inflammatory bacterial products to the system (99, 100).
Glucose homeostasis is finely balanced and the mild post-
prandial transient inflammatory response associated with
glucose intake may in fact be beneficial and represent a form
of parainflammation (101, 102). The trouble begins when this
adaptive mechanism breaks down.PRIMARY AND SECONDARY FEATURES
OF DIABETIC RETINOPATHY
The above preamble is especially relevant to the pathogenesis of
DR, since DR develops against a background of chronic systemic
inflammation. It follows that circulating inflammatory mediatorsFrontiers in Immunology | www.frontiersin.org 7will modify retinal function. Altered glucose metabolism has
primary and secondary effects on the retina. Primary effects are
the result of disturbed glucose and lipid metabolism directly
affecting retinal cells including neural cells, supporting cells (glia,
microglia, Müller cells) and vascular cells, including endothelial
cells, pericytes as well as intravascular cells. Secondary effects of
diabetes on the retina are the consequences of the primary insults.
Thus early functional changes to the retina in diabetes include
characteristic changes in the electroretinogram (103) as well as
defects in autoregulation of vascular blood flow (104) which may
be detectable before clinically visible signs of retinopathy appear.
In addition, there are direct neurodegenerative changes to glial
cells (105, 106) and to photoreceptors (107, 108). Recent reviews
of diabetic retinopathy faithfully document the many pro-
inflammatory changes which occur in the retina, involving
nitric oxide (NO), cyclo-oxygenase (109), leukotrienes, vascular
endothelial growth factor (VEGF) and more but do not highlight
the fact that one of the central pro-inflammatory mediators is
glucose at high concentration (110). Not only will an altered
systemic metabolism of diabetes directly affect retinal tissues
leading to sequential changes in all these other mediators, it is
also the case that both the retinal circulating leukocytes as well as
the retinal vascular endothelium will not be spared and will have
secondary retinal damaging effects from the onset of diabetes.
Indeed, the constant trafficking of hyperglycemia-activated pro-
inflammatory leukocytes through a retina in contact with
endothelial cells bathed in toxic levels of high blood sugar is
inevitably bound to have a deleterious effect.
The classical clinical signs of DR are well known (Box 1).
Microaneurysms (m/a) are the hallmark of DR and the condition
cannot be diagnosed in their absence (Figure 5a). However, m/a
are also a feature of other retinal diseases such as hypertensive
retinopathy (HR) and they also occur in non-retinal tissues. M/a
are surrounded by small but increasing areas of retinal ischemia,
which is clinically detectable by retinal angiography using a
fluorescent dye. Thus focal micro-patches of retinal ischemiaBOX 1 | Clinical Signs of Diabetic Retinopathy (DR)*.
The signs of DR normally develop sometime (years) after the onset of diabetes. However, they do not occur in all patients (111), and some subsets of diabetes may be
protected from DR. DR is uncommon in childhood diabetes but typically develops in adolescence. The clinical features progress as seen by ophthalmoscopy, fundus
fluorescein angiography (FFA) optical coherence tomography (OCT) and OCT-angiography (OCT-A) are described below.
Clinical finding by ophthalmoscopy* FFA OCT/OCT-A
microaneurysm focal ischemia
dot haemorrhage fluorescein dye leakage patchy thickening
blot haemorrhage capillary non-perfusion capillary non-perfusion
venous irregularity




gliosis retinal surface traction
neovascularization of optic nerve head/periphery (PDR **) severe dye leakage severe non-perfusion
retinal thickening/macular edema extensive dye leakage increased retinal thickness, intraretinal cysts




*Figures 5, 6 ** PDR: proliferative diabetic retinopathy.November 2020 | Volume 11 | Article 583687
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retinopathy (Figure 5b). An associated early sign is breakdown
of the blood retinal barrier evidenced clinically on angiography
as fluorescein dye leakage which permeates retinal tissues and
spills over into the vitreous cavity (Figure 5c). Progressively
larger areas of retinal ischemia in time are followed by
intraretinal microvascular abnormalities (IRMA) (Figure 5d)
leading to neovascularisation/proliferative DR (PDR, Box 1)
with crops of new vessels sprouting from the optic nerve head
and the mid-peripheral retinal venules. These vessels ultimately
haemorrhage into the vitreous cavity due to fibrotic/gliotic
vitreoretinal adhesion and traction, and finally end with retinal
detachment (Figures 6b, c) (Box 1). Severe non-proliferative DR
(NPDR) is characterized by increasing retinal oedema, venous
abnormalities (“beading”) (Figure 6) and deposits of lipid-rich
exudates often concentrated around the macula/fovea. Both PDR
and macular edema (Figure 6a) are driven by high local levels of
hypoxia and release of VEGF (110, 113–115). Sight loss from
macular edema is typical of T2D while intraocular haemorrhage
and tractional retinal detachment are more common in T1D,
although both causes of sight loss frequently occur in either type
of diabetes. In terms of frequency therefore macular edema is the
more common cause of visual disability related to diabetes.
All of the above features of DR are late events, including sight
loss (which is a very late event) since they develop at variablyFrontiers in Immunology | www.frontiersin.org 8prolonged times after the onset of hyperglycemia and
dyslipidemia. M/a [so-called “background retinopathy” (95)] do
not appear until years of diabetes have elapsed. Micropatches of
retinal ischemia are not detected unless fluorescein angiography
is performed which is rarely clinically indicated in a normally
sighted individual. It is possible that with new imaging techniques
such as optical coherence tomography angiography (OCT-A),
research projects to identify the earliest clinical signs might
uncover more subtle vascular signs but there are limited data so
far (116). Interestingly OCT-A studies confirm that capillary
vessel changes occur prior to the onset of clinically overt diabetic
retinopathy. Historically, pathological studies consider pericyte
loss to be the earliest sign in retinal capillaries, with capillary
“drop-out”, acellular capillaries and microaneurysms also
prominent features [reviewed in (117)]. However, post-mortem
trypsin digest, retinal flat mount studies on samples with minimal
signs of DR are usually performed sometime after the onset
of diabetes.
Experimental models of DR do not fully replicate the features
of DR in humans, particularly the later changes of PDR. In
addition, only primates have a macula thus limiting studies of
macular oedema. However, microaneurysms and retinal
capillary non-perfusion/ischemia are features of DR in the
mouse and rat (87). Several models of diabetes in rodents are
available (118) but the most frequently used is the streptozotocinFIGURE 5 | Retinal fundus images of diabetic retinopathy. (a) fundus photograph showing microaneurysms (arrows); (b) late fluorescein angiogram showing
numerous microaneurysms (white dots) with small surrounding dark patches indicating focal retinal ischemia; (c) late fluorescein angiogram showing abnormal
capillary permeability as small areas of diffuse dye leakage from microaneurysms (yellow arrows) surrounding a large dark, non-perfused patch of retinal ischemia
(white arrow); (d) ultrawide field fundus image showing optic nerve head (yellow arrow), intraretinal microvascular abnormality (blue arrow) and pre-retinal
haemorrhage (white arrow) (112).November 2020 | Volume 11 | Article 583687
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pro-inflammatory effects of STZ but its chemical toxicity is
relatively islet specific and by causing selective death of beta
cells resembles both Type 1 and Type 2 diabetes. Its pro-
inflammatory effects may be due to beta cell destruction as in
T1D (see above). In addition, by modifying the induction
protocol, both acute and chronic models can be established in
the STZmouse, the latter being the preferred model, and the time
of onset of diabetes (hyperglycemia) can be definitively set.
Clinical signs of DR in the STZ mouse are few. Occasional m/
a can be detected. Prior to the introduction of rodent fundus
imaging techniques (119, 120), the earliest signs of DR such as
pericyte loss and capillary drop out were not detected until
several months after onset of diabetes.DIABETIC RETINOPATHY IS PRIMARILY A
VASCULAR DISEASE IN WHICH THE
ENDOTHELIUM IS THE TARGET OF
ATTACK
Because the clinical features of DR predominantly involve
changes in the retinal vessels, DR is considered by many to be
primarily a small vessel disease caused principally by endothelial
cell damage due to disrupted metabolism. There is little doubt
that the vascular changes modify retinal function since, as Rafii
et al. say, capillary endothelial cells are the “gatekeepers ofFrontiers in Immunology | www.frontiersin.org 9cellular metabolism” in the tissues (121). Endothelial cells also
have a secondary role in providing trophic and other factors
essential to tissue health which is unrelated to their role in tissue
perfusion and nutrient transport functions. This “angiocrine”
function is mediated by factors such as VEGF, fibroblast growth
factor (FGF), thrombospondin (TSP)-1, and others and is tissue
specific [reviewed in (121)]. The neurovascular unit of the CNS
(122) probably fulfils this role in the retina. In diabetes, capillary
endothelial cells are liable to damage with leakage of glucose-rich
plasma into retinal tissues (Figures 7 and 8) and an increased
retinal cell glucose flux with generation of reactive oxygen and
nitrous oxide species (87, 123–125). Photoreceptor dysfunction
(108), Müller cell/glial cell activation with gliosis (105, 126), and
ganglion cell loss with overall retinal thinning are well
documented (108, 127). However, these events occur after
sustained initial damage to the capillaries (years in humans,
months in rodent models) and are therefore secondary to
microvascular disease. In addition, they do not correlate
directly with vascular damage (108). The question therefore is
whether the microvascular disease is primari ly an
endotheliopathy due to direct glycolipid toxicity or is due to a
ramping up of the MS and systemic inflammation leading to
secondary endothelial damage. This important question has
implications for therapy.
The classic signs of pericyte loss, basement membrane
thickening and acellular capillaries, described as the earliest
pathological changes of DR in humans (117) also occur in the
STZ mouse. As in humans, they are reported as some of the firstFIGURE 6 | (a) Optical coherence tomography (OCT) images of diabetic macular oedema: fundus image to indicate plane of “optical section” (red arrow) through
the retina showing macular oedema/retinal cysts (white arrows) in image on the right; (c) ultrawide angle, pre-surgical image of pre-retinal (subhyaloid) haemorrhage
in the vitreous cavity obscuring the optic nerve and macula; (c) post-surgical view of same eye in (b): vitreous cavity is now clear and optic nerve head (white arrow)
and macula (yellow arrow) are visible.November 2020 | Volume 11 | Article 583687
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the onset of hyperglycemia and diabetes. In addition, they are
not unique to the retina: they are in fact manifestations of a
diabetes-related vasculopathy also seen in many tissues,
including the choroid (128, 129), the heart (130, 131),
peripheral nerves (18), and the kidney (19). Moreover, retinal
microaneurysms, acellular capillaries, and other vascular
changes occur in the absence of diabetes, for instance, in aging
(132) and hypertension (133). Thus, while the microvascular
changes are characteristic of DR they are not specific and might
be better considered caused by several mechanisms, one of which
is glycolipid toxicity of diabetes. The question then is how do
these various insults cause microvascular disease and what are the
initial events?Frontiers in Immunology | www.frontiersin.org 10For obvious reasons, the earliest pathological signs of
microvascular DR in humans are difficult to record.
Experimentally, both in vivo and in vitro loss of endothelial
cells and pericytes due to apoptosis is a recognized consequence
of exposure to high glucose levels (125, 134, 135). Endothelial
cells have a defined life span and in healthy individuals there is a
natural turnover, replenished from bone marrow precursors
(136, 137). Endothelial cells are subject to the constant flow of
blood under pressure and particularly at branching points are
exposed to stress. Capillaries accommodate only a single file of
flowing cells with individual leukocytes interspersed within
columns of red cells (rouleaux). This has recently been
visualized in the retinal capillaries in vivo non-invasively using
adaptive optics (138) and periods of red blood flow stasis of
several second duration were observed and attributed to
“interactions” with leukocytes as well as turbulence at capillary
branching points. The passage of leukocytes in retinal vessels also
explains visual entoptic phenomena (104). Capillaries are
dynamic structures and can respond to the demands of the
tissue by changing their perfusion status (139). This is
particularly seen in the retina where the perifoveal capillary
network can be seen to undergo changes in its angiographic
pattern as shown very clearly on OCT-A (139). In diabetes, these
changes are more pronounced (140) and pathologies such as
microaneurysms, vascular leakage and dot and blot
haemorrhages come and go as vessels open and close (141).
Indeed it is also possible for areas of vascular occlusion and
retinal non-perfusion to become re-perfused in early diabetic
retinopathy (142). Reperfusion occurrs via two mechanisms:
recanalization and focal intraretinal neovascularization (see
above, IRMA). It can be seen therefore that permanent
changes such as pericyte loss and acellular capillaries are akin
to findings from an archaeological dig, representing damage and
decay from events long past.
There is no argument concerning the presence of vascular
damage in diabetes. Endothelial cells are under stress and tend to
apoptosis, an effect which could be due to the direct effects of
high glucose (28) or to reactive oxygen or nitrous oxide species
(125). A reduction in tissue perfusion and oxygenation, due to
lack of blood flow in capillaries which have lost their endothelial
lining will unquestionably lead to tissue dysfunction, which
particularly applies to the retina with its high oxygen usage
(139). In addition, capillary leakage, and fibrin deposition in the
extracellular ischemic space will compound the pathology
(Figure 8). The question is: what causes the capillary non-
perfusion? Is it a chemical toxicity to the vascular endothelium
and supporting pericytes caused by exposure to high levels of
glucose and dyslipidemia of diabetes, thus leading to capillary
dysfunction and inability to allow blood stream flow? Or is there
a sustained intravascular obstruction to flow?
As detailed above, the clinico-pathological signs of DR can
also be reproduced in other clinical diseases and experimental
situations. Severe HR has many of the features of advanced DR
with haemorrhages, capillary closure and nonperfusion, venular
dilatation, and ischemia and, as for the early stages of DR, these
changes are reversible if the blood pressure can be controlled. InA
B
FIGURE 8 | Diagram of ischemic retina: (A) area of ischemia and oedema;
(B) representation of tissue fibrin deposition and macrophage infiltration
surrounding non-flowing venule.A
B
FIGURE 7 | Diagrams of retinal circulation: (A) normal blood flow from
arterioles (red) through capillary network to venules; (B) abnormal blood flow
in diabetic retinopathy showing microaneurysms, capillary loss (drop-out),
retinal ischemia and venous beading.November 2020 | Volume 11 | Article 583687
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changes pathologically (143). Furthermore, hyperlipidemia
(HFD) without diabetes or raised blood pressure also generates
a similar pathology suggesting that the metabolic changes alone
are sufficient to cause the vasculopathy (79, 144). The question
therefore remains whether the vessel is faulty or the vessel
contents are at fault. However, this may be less important in
practice than it appears since once the metabolic changes become
pathogenetic, both endothelial cell and blood leukocyte
physiology will be altered, probably simultaneously, thus
promoting abnormal leukocyte-endothelial interactions,
i.e., adhesion.DIABETIC RETINOPATHY IS AN
INFLAMMATORY DISEASE
The earliest clinical feature of DR, i.e., the m/a, highlights the
dynamic nature of the disease. How m/a form is unclear but they
are considered to be regions of vessel wall dilatation or
outpouchings. However, an alternative view is that they
are blind ends of occluded capillaries, often at branching
points, representing aborted attempts at revascularisation/
neovascularization (117) (Figures 5c, d and 6b). As stated
above, m/a are associated with micropatches of retinal
ischemia (non-perfusion) which in essence equate to areas of
focal capillary occlusion. M/a also, as stated above, come and go
(141) indicating that reperfusion of discrete areas of retinal
ischemia has taken place. Indeed a reperfusion of ischemic
retina has been documented by fluorescein angiography (142).
This is particularly evident in the early stages of DR but as time
goes by the numbers of m/a and the areas of retinal ischemia
increase. This suggests an attritional process of microvascular
occlusion which is best explained by increased numbers of non-
perfused capillaries each trapped at different times by a single
adherent leukocyte as dictated by capillary dimensions (145).
This is termed leukostasis but is more correctly described as flow
stasis caused by trapped/adherent leukocytes. Cells travel in
single file in capillaries and transient leukocyte arrest occurs in
healthy individuals albeit only in occasional vessels and usually at
branching points due to turbulent flow. Capillary non-perfusion/
reperfusion also occurs in healthy retina and indeed is a process
of dynamic vascular remodelling essential to retinal health (see
above) (139). In DR, this process falters and intravascular
leukocyte arrest becomes more frequent and prolonged, and
sometimes irreversible, with capillary occlusion, vascular leakage,
retinal ischemia and damage, and hypoxia, leading eventually to
the later secondary changes of severe NPDR and PDR (see Box 1).
In the early stages, remodelling and reperfusion are possible but
with time the ailing vasculature cannot cope with the constant
barrage of circulating, adhesive leukocytes.
It is important to consider that increased leukocyte trapping/
leukostasis parallels the increase in blood glucose/dyslipidemia
(146, 147) but this has been attributed by some authors to
changes in the endothelium rather than the circulating
leukocytes (148). As detailed above, hyperglycemia activatesFrontiers in Immunology | www.frontiersin.org 11circulating leukocytes which are then liable to adhere to vessels
walls (149, 150). Just as there is a progression from glucose
homeostasis through prediabetes to overt disease, there is a
coincident change in leukocyte/vessel interaction, from
occasional transient leukocyte trapping to multiple sites of
prolonged leukostasis with fewer successful reperfusions, until
eventually networks of capillaries are permanently occluded, lose
their endothelial lining and pathologically present as areas of
reduced capillary density and acellular capillaries in the later
stages of DR (151) (Figures 5 and 7).
The concept of activated leukocytes causing capillary
occlusion was first proposed by Schroder et al. (152) who
demonstrated trapped granulocytes and monocytes within
retinal capillaries. Further studies found that increased levels of
circulating soluble adhesion molecules (ICAM-1, VCAM-1, P-
selectin) not only occurred in diabetes but correlated with the
severity of DR (91). Importantly, increased levels of adhesion
molecules (ICAM, VCAM and PECAM) were often present
contemporaneously with the onset of diabetes, were closely
related to the level of HbA1c and were considered to be
measures of endothelial cell damage (153). Soluble adhesion
molecules are shed from endothelial cell surfaces usually after
contact with flowing cells. In the circulation, increasing levels are
more likely a measure of the increasing number of “hits” in terms
leukocyte-endothelial cell adhesive interactions, which does not
occur in health. In diabetes, obesity, and the MS, circulating
leukocytes show signs of activation related to chronic low levels
of systemic inflammation, driven either by beta cell loss or IR
(see Is Inflammation in Diabetes a Direct or an Indirect Cause of
Complications above). This manifests as increased levels of
reactive oxygen species (ROS) (123, 154) and iNOS (87) as
well as increased surface levels of the integrin CD11b (155)
and other molecules (see below). Increased circulating ROS
directly damage the vascular endothelial surface, specifically its
hyaluronan - rich protective glycocalyx, which depolymerises
and thins, eventually exposing the plasma cell membrane to
direct contact with activated leukocytes (156, 157).
Increased leukocyte-endothelial cell adhesion was inferred
from experiments showing that leukostasis was reduced both by
the blockade of adhesion molecules using monoclonal antibodies
as well as in ICAM−/− and VCAM−/− mice [reviewed in (106)].
Such mice also had reduced late vascular changes of DR
including reduced pericyte loss and acellular capillaries
compared to untreated diabetic mice. However, increased
expression of adhesion molecules on the endothelial cell
surface is not necessarily a measure of inflammation and could
simply be an expression of disordered metabolic state of the cells
due to diabetes. More compelling evidence of a primary role for
inflammation in DR rests on the activated state of circulating
leukocytes. Activation of innate immune cells is reflected in
increased levels of co-stimulatory molecules such as CD40,
CD80, and CD86 as well as MHC Class II. In myeloid cells
generally, increases in CD11a, b and c also indicate heightened
activation status. Both hyperglycemia and hyperinsulinemia can
increase CD40 levels in monocytes and platelets (158) while
inhibition of CD40 expression prevents both leukostasis andNovember 2020 | Volume 11 | Article 583687
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loss/degeneration and inflammation (159, 160). Increased levels
not only of CD40/CD40L but Toll-like receptors, ER stress,
CCR5 and Fc-g receptors (CD32 and CD64) are characteristic
of the MS (161), and specifically, the CD11b+CCR5hi monocyte
is preferentially involved in early onset STZ diabetes-induced
leukostasis (145). The pro-inflammatory profile of monocytes in
diabetes, including increased expression of CD80, has long been
recognized (162). However, it is important to realize that chronic
inflammation in diabetes is dysregulated; indeed, the
performance of inflammatory cells in responding to acute
disease/injury is impaired in patients with diabetes compared
to healthy individuals, perhaps related to skewed myelopoiesis
(24, 163).
Overall, these correlations although compelling are not
definitive proof that activated leukocytes, and by inference a
background of inflammation, are the cause of the retinal non-
perfusion and ischemia in diabetes and MS. Ischemic retina is
widely accepted as a source of VEGF, either from retinal cells
such as Müller cells (164) and ganglion cells (165) or from the
activated leukocytes themselves (166). It is also possible that the
activated leukocytes induce Müller cell production of VEGF
(167). The beneficial effects of blocking VEGF in DR clearly
identify this mechanism. VEGF is known to be a major player in
inflammation and so inflammation as the root cause of
pathology, including the pathology of DR remains a strong
concept. However, the situation is complex since VEGF
exacerbates leukostasis and blocking the VEGF receptor
permits retinal reperfusion (168). Only by preventing
leukocyte-driven inflammation can the question be resolved.
A deeper look at leukostasis/leukocyte arrest generally is
important since it occurs infrequently in healthy vessels, small
and large. All vessels are subject to the stress of blood flow and in
capillaries the constant intimate contact with trafficking cells.
Indeed the endothelial hyaluronan-rich glycocalyx appears
designed to protect the endothelium from flow-cell damage
(156, 157). Endothelial cells therefore require a mechanism for
repair/turnover which is provided by EPCs (169). Both
haemopoietic stem cells (170) and EPC arise from a common
source embryologically [termed the haemothelium (171)] and in
the bone marrow occupy separate niches (95). HSC-derived
stromal macrophages guide vascular EPCs to differentiate and
migrate/mobilize into the circulation. Here, these rare cells are
attracted to sites of endothelial injury and settle contiguously
into the existing monolayer.
Evidence for this repair process has been suggested most
recently, in a study of aging and endothelial cell turnover in
retinal vessels. As the endothelial cell becomes senescent,
neutrophil leukocytes adhere to the dysfunctional cell and
engage in its removal (172). Apparently, the aging endothelium
sends out a “secretome” to attract neutrophils which, as activated
cells, release neutrophil extracellular traps (NETS) to surround
and clear the diseased cell. This allows remodelling of the vessels
which is achieved by replacement of the defective endothelial cell
by circulating/rolling EPCs as suggested above. Diabetes is
considered a type of accelerated aging (173, 174) and thisFrontiers in Immunology | www.frontiersin.org 12mechanism of endothelial repair might be overactive in diabetic
retinal vascular disease. Indeed, it is possible that defects in this
repair mechanism may underlie microvascular occlusive retinal
vascular disease as suggested above. If this is the case, then the
primary abnormality would be attributable to the endothelium in
diabetic vascular disease, but would depend on normal, effective
leukocyte activation and NETosis to prevent disease.
However, in diabetes, the source of myeloid leukocytes (i.e., the
bone marrow) is a target tissue, not only causing hyperglycemic
activation of leukocyte progenitors but impairing EPC mobility
and preventing adequate repair of damaged vascular endothelium.
In addition, the balance between bone marrow EPC’s and HSC’s is
disturbed (175). It is possible that the increased leukostasis
observed in DR represents a failure of EPC-mediated repair by
activated myeloid progenitors to fill the gap. The result is however,
the opposite, in that the activated, but dysregulated, leukocyte
causes further damage to the endothelium with progression to an
acellular capillary.
In this scenario, a damaged, prematurely aged endothelium
might be seen as the primary abnormality in the microvascular
complications, particularly retinopathy, of metabolic disease
including diabetes. However, this may be a somewhat pointless
discussion since both players, i.e., the activated leukocyte and the
damaged endothelium, are both metabolically disturbed from the
onset of disease.LEUKOCYTE ACTIVATION IN DIABETES—
WHAT IS THE EVIDENCE?
In diabetes, the initial site of injury is the islet beta cell (discussed
above) leading to cell death with local and systemic cytokine and
chemokine release. This becomes a systemic challenge mediated
by hyperglycemia in a self-perpetuating cycle which affects all
tissues including the bone marrow (Figure 9). Thus, bone
marrow-derived circulating leukocytes become persistently
activated in situ and remain so as they enter the circulation
and populate the tissues. This can occur as early as two weeks
after the onset of hyperglycemia (145).
How does glucose activate mononuclear cells? Monocytes
express GLUTs 1, 3, and 5 which they use to take up glucose by
facilitated diffusion, i.e., in a concentration dependent manner
(176–178). GLUT 1 in particular is upregulated in pro-
inflammatory macrophages to support the upregulation of
glycolytic metabolism (48, 179). Macrophages can also
accumulate glucose against a concentration gradient in a glucose-
deprived environment using sodium-glucose transporters (180,
181). However, GLUT 1 is the major transporter of glucose into
monocyte/macrophages and is relatively insulin independent, i.e.,
uptake is determined by the extracellular glucose concentration.
High levels of ambient glucose together with activation through
exposure to tissue damage-release of cytokines such as IL-1b and
TNF-a activate leukocytes to increase glucose uptake and
metabolism, predominantly through aerobic glycolysis (Warburg
effect) and increased hexokinase (Hx) activity. Hx converts glucose
to glucose-6-phosphate in the initial stages of glycolysis and is itselfNovember 2020 | Volume 11 | Article 583687
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Indirect Cause of Complication) which positively regulates leukocyte
activation (84) while the glucose sensor pyruvate kinase M2
(PKM2) (see Figure 3), which normally combines with fructose
1,6-bis-phosphate to complete the production of phospho-enol
pyruvate and pyruvate, is partially diverted to the inactive
monomeric enzyme (182, 183). Monomeric PKM2 translocates to
the nucleus where it activates hypoxia inducible factor-1a
associated genes required for the production of VEGF (182, 183).
HIF-1a is the driver of metabolic reprogramming in monocyte/
macrophages as well as of angiogenic responses through VEGF (48,
179) (Figure 3).
Thus, activated circulating pro-inflammatory leukocytes
trapped in the retinal microcirculation are not only agents of
capillary non-perfusion and retinal ischemia but are sources of
factors which can induce increased vascular permeability
(VEGF/VPF) as well as induce local angiogenic responses (e.g.,
budding of m/a) (184). This adds to the already induced source
of VEGF from activated retinal cells such as microglia andMüller
cells (see above) but, because of its location inside the vessel, the
activated, glucose-induced pro-inflammatory leukocyte can have
direct access to the glycocalyx-depleted endothelium. Trapped
leukocytes within the microaneurysm have been elegantly
demonstrated by electron microscopy (185). As detailed above,
in diabetes leukocytes express increased levels of activation
molecules while the high glucose-exposed endothelium is
likewise under stress and expresses the complementary surface
adhesion molecules. Activated leukocytes in the presence of high
glucose also promote inflammation by shunting of accumulating
succinate intended to go through oxidative phosphorylation toFrontiers in Immunology | www.frontiersin.org 13production of HIF-1a (48) while excess succinate released
extracellularly acts as a stimulant for further leukocyte
activation and recruitment (186) (Figure 2).
As indicated above, glucose and its products comprise one set
of metabolites which can induce leukocyte activation while
increased lipid, dyslipidemia, and particularly “bad” lipids
indirectly activate leukocytes via cytokine release as a result of
dysregulated sphingolipid metabolism (79). As for DR, the
retinopathy in HFD-diet fed mice appears to be linked to
increased adhesion molecule expression (187). The common
denominator in this pathology seems therefore to be chronic,
but dysregulated, leukocyte activation which has widespread
effects on tissues generally and the retina in particular (Figure 9).LEUKOCYTE ACTIVATION IN DIABETES—
WHAT IS THE MECHANISM?
Leukocyte activation in response to pathogen challenge or to
tissue damage/injury follows a now well-defined path involving
PAMP - PRR interactions, activation of distinct signaling
pathways such as TLR - Type 1 interferon and C-Type lectin -
inflammasome signaling as well as the cGAS-cGAMP-STING
pathway, resulting in cytokine release with positive feedback
amplification via central mediators such as IL-1b and TNF-a
(188). How leukocytes become activated in diabetes and the MS
is less clearly defined but probably follows a similar pathway
(Figure 2). Beta-cell damage in T1D leads to IL-1 release which
can initiate the process but later in T1D and, from the beginning,FIGURE 9 | Diabetes, The Metabolic Syndrome and Retinopathy. Diabetes caused by nutrient overload or autoimmune disease leads to beta cell dysfunction/loss
inducing a chronic pro-inflammatory state in which leukocyte activation promotes early microvascular disease. This causes secondary tissue damage (retinopathy,
nephropathy, and peripheral neuropathy). Direct damage to the tissues by chronic glycolipid toxicity develops more slowly compounding the pathological changes.November 2020 | Volume 11 | Article 583687
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Hyperglycemia from beta cell loss or from nutrient overload,
combined with microbiome-associated dysbiosis (100, 189) and
low level endotoxemia may be sufficient to sustain low-level
chronic leukocyte activation (Figure 9). Increased aerobic
glycolysis and hexokinase activity (84) due to heightened
glucose flux, intracellular accumulation and extracellular
release of succinate with HIF-1a-gene activation and VEGF
production (see above), are likely to contribute to overall low-
level chronic leukocyte activation. Indeed, mTOR and HIF-1a
mediated aerobic glycolysis underpin innate immune cell
memory which may contribute to the ready activation of
myeloid cells chronically exposed to metabolic stimuli. Most
recently, it has been shown that circulating myeloid (monocyte/
macrophage) cells in patients with diabetes, and in STZ-
experimental mice, have elevated levels of pSTAT3, a cell
signaling regulatory molecule while specific deletion of SOCS3
in the same cells (LysM-SOCS) leads to increased leukostasis and
capillary drop out (190). Cytokine release, as well as damage-
associated ATP release, entrains multiple signaling pathways
including: (a) IL-1b/IL-1r signaling involving the Mydd88/Src/
Asc-NLRP3/inflammasome pathway; (b) IL-6/IL-6r - MAPK; (c)
TNFa/TNFar and MAPK/NFk B signaling; and (d) ATP/P2x7R -
inflammasome pathway. Increased glycolysis by activated
leukocytes also increases signaling through the succinate/
succinate receptor and lactate is no longer seen as a bit player
in this process. Lactate as well as being a source for mitochondrial
respiration and energy via gluconeogenesis, can directly modify
histone proteins and epigenetically modify gene activity
(lactylation) (191).
However, metabolite/nutrient-associated leukocyte activation
as in the MS and diabetes (both T1D and T2D) is different from
leukocyte activation due to pathogen challenge. As indicated
above, myelopoiesis is increased but there is a disconnect
between HSC production and EPC mobilization such that
vascular endothelial repair is defective. In addition the quality
of macrophages in wounds is shifted more toward inflammatory
macrophages than arginase+ wound healing macrophages such
that wounds don’t heal well. These aspects of leukocyte
activation have direct relevance to DR in which the retina
attempts to restore tissue integrity at sites of retinal ischemia
but may be unsuccessful (see above).
Several of these pathways are kinase dependent and regulated
by phosphatases (192). The ubiquitous protein tyrosine
phosphatase PTP1B has been shown to be integral to glucose
and lipid metabolism in several tissues and control of energy and
adiposity varies with the tissue location of PTP1B (193–197).
Importantly, as indicated above macrophage and neutrophil
specific PTP1B appears to drive a pro-inflammatory function
since deletion of PTP1B specifically in myeloid cells protects
against HFD and LPS-induced inflammation and endotoxemia
(81, 198). A possible therapeutic intervention through modifying
these signaling pathways might be possible.
Whatever the precise mechanism, chronic inflammation with
activated leukocytes and circulating inflammatory mediators is
clearly a significant feature of diabetes, obesity and the MS, isFrontiers in Immunology | www.frontiersin.org 14present from the onset of disease, and appears to be a direct cause
of the characteristic microvascular disease leading to overt
clinical symptoms such as DR (Figure 9).DIABETIC RETINOPATHY—IS THERE A
ROLE FOR ADAPTIVE IMMUNITY?
T1D is considered to be an autoimmune disease induced by viral
infection (see above) while in T2D there is a marked reduction in
AT Tregs, the homeostatic regulator of immune tolerance (61,
199). In all cases definitive autoantigens have not been identified
but activation markers on systemic T cells are well recognized
(see above). Autoimmunity as a driver of disease progression in
DR has also been proposed. The constant, repetitive leukocyte-
endothelial cell adhesive events occurring in the diabetic retina in
time lead to significant retinal ischemia, retinal damage and
release of damaged retinal proteins. Many tissue specific retinal
proteins act as autoantigens although these mostly reside in the
photoreceptors which are only affected once the disease is
significantly advanced. Inner retinal damage to integral Müller
cells, neurones and retinal glial cells also release autoantigenic
peptides. Increased levels of various auto-antibodies have been
detected in patients with DR (200–203) including one to
hexokinase 1 (204), while, in one study, DR was more common
in the absence of autoantibodies (e.g., to GAD). The evidence,
therefore, for an autoimmune pathogenesis in DR is relatively
limited (205). Interestingly, in the context of premature aging of
endothelial cells in DR (see above), there also appears to be an
accumulation of senescent T cells in the circulation of T2D patients
with impaired glucose metabolism (206). Most recently, in a
prospective pilot study, increased numbers of circulating
neutrophilic leukocytes with a reduced number of T cells during
the development and progression of DRwas observed (207). At this
stage, it is difficult to define the role of adaptive immunity in DR.
However, the possibility remains. Circulating T cells participate
in retinal leukostasis creating the potential for T cell activation by
bone marrow derived DC through presentation of retinal peptides.
Circulating pre-DC comprise a component of CD11b+myeloid cells
implicated in STZ-mouse DR-associated leukostasis and so all the
ingredients for an autoimmune component to DR are present in the
pathological retinal milieu. We have also recently shown that
inhibition of PTP1B in dendritic cells inhibits T cell activation
(208) and so the same mechanism that inhibits HFD-induced
obesity may also be active in diabetes-linked adaptive immunity.
Overall, however, it is likely that activation of innate immunity
begins the process of DR while any role for adaptive immunity is
likely to be in the further progression of the disease.PREVENTING AND TREATING THE
MICROVASCULOPATHY OF OBESITY/THE
MS/AND DIABETES
Many strategies have been proposed for prevention and
treatment of the complications of diabetes. In the case of DR,November 2020 | Volume 11 | Article 583687
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threatening. PDR and severe non-PDR are treated by retinal
laser photocoagulation therapy (LPT) based on data from the
Early Treatment for Diabetic Retinopathy Study (ETDRS) and,
since its introduction, LPT has become the standard treatment,
although the original evidence is not entirely robust [reviewed in
ref. (209)]. LPT is destructive and areas of retinal damage
(atrophy) may increase long after end of treatment (210, 211).
Its mechanism of action is unclear. Reduction in VEGF release
from oxygen starved cells in the retina is the accepted
explanation for the effectivity of LPT. This could include
retinal inflammatory cells such as macrophages as well as
parenchymal cells since LPT induces indiscriminate and
extensive cell death. Randomized controlled clinical trials
(RCT’s) have shown that inhibiting VEGF production by using
intravitreal anti-VEGF agents is also effective, but not entirely so,
particularly for macular edema [reviewed in (212–214)],
indicating that there are other factors at play in the tissue fluid
accumulation. In addition, the same studies showed that
intravitreal steroid injection may be equally effective as anti-
VEGF therapy in the short term and have a more durable long
term effect. A combination of both treatment modalities (LPT in
association of anti-VEGF) seems to be the most beneficial
approach for many patients with advanced DR.
Few RCT have explored preventive therapies for DR, i.e.,
clinical trials initiated at time of diagnosis of diabetes. The first
prospective study of intensive glycemic control (IGC) vs.
conventional therapy clearly demonstrated a beneficial effect of
strict blood glucose control in preventing or delaying onset of DR
in T1D (215–217). Furthermore, early initiation of strict
glycemic control has had long lasting beneficial effects (218). A
landmark study in T2D, the United Kingdom Prospective
Diabetes Study (UKPDS) also clearly showed that IGC reduced
the incidence of DR and sight loss (219) and later re-analysis of
this and other studies confirmed this finding. However, in both
the DCCT and the UKPDS the risk of hypoglycemic attacks has
prevented IGC from being uniformly and strictly applied
(220–222).
A search for a safer systemic approach to preventing or
delaying development of complications has re-examined the
benefits of the lipid-lowering drug fenofibrate (223, 224), but
the, albeit uncommon, side-effects have also prevented its
widespread use. Experience with the liberally prescribed statins
has also been examined as a possible means of eliminating the
hyperlipidemic risk factor for DR, and there is some evidence
from RCT’s (225–227) but a critical analysis of published data
suggests that the quality and reporting of the data may be flawed
(228). Experimentally, rosuvastatin has been shown to inhibit
leukostasis in which the effect appeared to act on the endothelium
rather than the leukocytes, thus pointing to a primary metabolic
defect in the endothelium initiating leukostasis (145).
However, both fenofibrate and statins have more than a lipid
lowering effect. In particular, there is considerable evidence that
anti-inflammatory effects of statins are its a major mechanism of
action whether it is by acting on the endothelium or directly onFrontiers in Immunology | www.frontiersin.org 15inflammatory cells (229–231). Directly inhibiting inflammation
in the treatment of diabetes has a long history, even to the early
use of salicylates [reviewed in (232)], and has been shown to have
some effect. However, for control of DR, such treatments have
been introduced too late: as outlined in this review, pathologies
like macular edema are late, if not very late, events and
permanent structural damage has already been done by the
time vision is affected. Therefore, the likelihood of reversing
disease is small, but does happen. Patients with mild background
retinopathy not involving the macula have had chronic
inflammatory disease for many years and early treatment
before vision is threatened is the only way blindness can be
stopped. The complications of diabetes are initiated from the
onset of disease and by controlling the triggers of inflammation
such as hyperglycemia and dyslipidemia loss of vision can be
prevented as has already been shown (219). The possibility of
direct inhibition of IL-1 using the monoclonal anti–IL-1
antibody gevokizumab has been proposed but indications and
timing of therapy are not decided (233). A second anti-IL1
moAb, canakinumab has been proposed for inflammation
control in cardiovascular disease but not so far for diabetes
(97, 98). In the recent CANTOS trial no benefit for new onset
diabetes either in prevention or management was seen with
canakinumab (234). However, it may be that it will be very
difficult to design an RCT which could demonstrate an effect of a
broad-spectrum or molecule-specific anti-inflammatory strategy
while the fundamental metabolic defect affecting all cells,
including inflammatory cells, remains.CONCLUSION
Our understanding of the role of inflammation in diabetic
retinopathy is taking shape. While hyperglycemic glucose
toxicity affecting retinal cells and retinal vessel endothelium
undoubtedly induces retinal neurodegeneration and
vasculopathy respectively, these changes almost certainly are
not primary events. Instead, in T1D pancreatic inflammation
and beta cell damage/loss set a proinflammatory scene from the
outset while in T2D, AT/obesity-associated pre-diabetic
inflammation begets IR and hyperglycemia which amplifies
immune cell activation and continues the cycle of chronic
inflammation (Figure 9). Retinal vessel endothelial changes,
due in part to premature senescence, become an attractant for
leukocytes to adhere, probably as part of an endothelial repair
process. However, this fails to deliver, in part because the HSC-
niche in the bone marrow shifts from generating physiologically
reparative EPCs to pro-inflammatory macrophage-like progenitors.
Despite an overall increase in myelopoiesis, this fails to restore
vascular integrity, and instead promotes vascular occlusions and
increasingly large areas of ischemia especially in the retina. These
changes may be observed even before hyperglycemia as in the HFD
mouse model and in HR in humans and are a measure of the direct
effect of overall immune cell activation and immunometabolism
underpinning the MS and diabetes.November 2020 | Volume 11 | Article 583687
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